Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Charmacy Pharmaceutical Co., Ltd. Class H ( (HK:2289) ) has provided an update.
Charmacy Pharmaceutical Co., Ltd. reported 2025 operating revenue of RMB4.38 billion, a slight 1.15% decline from the prior year, reflecting a modest contraction in its pharmaceutical distribution business. The Hong Kong-listed company remains profitable but faces pressure on margins in a competitive healthcare market.
Net profit fell 13.16% year on year to RMB46.27 million, with earnings per share slipping to RMB0.4285, signalling softer profitability despite relatively stable revenue. The board nevertheless recommended a final dividend of RMB0.30 per share, indicating a continued commitment to shareholder returns even as earnings growth slowed.
The most recent analyst rating on (HK:2289) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Charmacy Pharmaceutical Co., Ltd. Class H stock, see the HK:2289 Stock Forecast page.
More about Charmacy Pharmaceutical Co., Ltd. Class H
Charmacy Pharmaceutical Co., Ltd. is a joint stock limited liability company incorporated in the People’s Republic of China and listed in Hong Kong. The group operates in the pharmaceutical sector, generating its revenue primarily from the distribution and sale of pharmaceutical products and related healthcare items to the mainland China market.
Average Trading Volume: 10,700
Technical Sentiment Signal: Sell
Current Market Cap: HK$627.5M
See more insights into 2289 stock on TipRanks’ Stock Analysis page.